Almirall extends aclidinium reach down under through Invida alliance
This article was originally published in Scrip
Executive Summary
Building on its existing relationship with Menarini, Almirall has licensed the commercial rights to its new chronic obstructive pulmonary disease (COPD) drug aclidinium bromide in Australia and New Zealand to the Italian firm's Asian subsidiary, Invida Holdings.